The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Fecal calprotectin and lactoferrin for the prediction of inflammatory bowel disease relapse
Open accessAbstract
BACKGROUND: The purpose of the study was to determine the role of fecal calprotectin and lactoferrin in the prediction of inflammatory bowel disease relapses, both in patients with ulcerative colitis (UC) and Crohn's disease (CD), in a large, long-term, follow-up study. METHODS: The prospective multicenter study included CD and UC patients who had been in clinical remission for 6 months. At baseline, patients provided a single stool sample for calprotectin and lactoferrin determination. Follow-up was 12 months in patients showing no relapse and until activity flare in relapsing patients. RESULTS: In all, 163 patients (89 CD, 74 UC) were included. Twenty-six patients (16%) relapsed during follow-up. Calprotectin concentrations in patients who suffered a relapse were higher than in nonrelapsing patients (239 +/- 150 versus 136 +/- 158 microg/g; P < 0.001). Relapse risk was higher in patients having high (>150 microg/g) calprotectin concentrations (30% versus 7.8%; P < 0.001) or positive lactoferrin (25% versus 10%; P < 0.05). Fecal calprotectin (>150 microg/g) sensitivity and specificity to predict relapse were 69% and 69%, respectively. Corresponding values for lactoferrin were 62% and 65%, respectively. The area under the receiver operating characteristic curve to predict relapse using calprotectin determination was 0.73 (0.69 for UC and 0.77 for CD). Better results were obtained when only colonic CD disease or only relapses during the first 3 months were considered (100% sensitivity). High fecal calprotectin levels or lactoferrin positivity was associated with clinical relapse in Kaplan-Meier survival analysis, and both fecal tests were associated with relapse in the multivariate analysis. CONCLUSIONS: Fecal calprotectin and lactoferrin determination may be useful in predicting impending clinical relapse-especially during the following 3 months-in both CD and UC patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Development of a Crohn's Disease Activity Index
Best, W. R., Becktel, J. M., Singleton, J. W., & Kern, F. (1976) · Gastroenterology · doi:10.1016/s0016-5085(76)80163-1 · Cited by 3,152
Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study.
Best, W. R., Becktel, J. M., Singleton, J. W., & Kern, F. (1976) · PubMed · Cited by 3,147
Cortisone in Ulcerative Colitis
Truelove, S. C., & Witts, L. J. (1955) · BMJ · doi:10.1136/bmj.2.4947.1041 · Cited by 2,767
Classification of Inflammatory Bowel Disease
Lennard-Jones, J. E. (1989) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365528909091339 · Cited by 2,011
Laboratory markers in IBD: useful, magic, or unnecessary toys?
Vermeire, S., Van Assche, G., & Rutgeerts, P. (2006) · Gut · doi:10.1136/gut.2005.069476 · Cited by 952
Tibble, J. A., Sigthorsson, G., Bridger, S., Fagerhol, M. K., & Bjarnason, I. (2000) · Gastroenterology · doi:10.1053/gast.2000.8523 · Cited by 759
Clinical, biological, and endoscopic picture of attacks of Crohn's disease
Modigliani, R., Mary, J.-Y., Simon, J.-F., Cortot, A., Soule, J.-C., Gendre, J.-P., & Rene, E. (1990) · Gastroenterology · doi:10.1016/0016-5085(90)90002-i · Cited by 699
Microscopic activity in ulcerative colitis: what does it mean?
Riley, S. A., Mani, V, Goodman, M. J., Dutt, S., & Herd, M. E. (1991) · Gut · doi:10.1136/gut.32.2.174 · Cited by 564
Costa, F., Mumolo, M. G., Ceccarelli, L., Bellini, M., Romano, M. R., Sterpi, C., Ricchiuti, A., Marchi, S., & Bottai, M. (2005) · Gut · doi:10.1136/gut.2004.043406 · Cited by 550
C-Reactive Protein as a Marker for Inflammatory Bowel Disease
Vermeire, S., Van Assche, G., & Rutgeerts, P. (2004) · Inflammatory Bowel Diseases · doi:10.1097/00054725-200409000-00026 · Cited by 513
A simple method for assessing intestinal inflammation in Crohn's disease
Tibble, J., Teahon, K., Thjodleifsson, B., Roseth, A., Sigthorsson, G., Bridger, S., Foster, R., Sherwood, R., Fagerhol, M., & Bjarnason, I. (2000) · Gut · doi:10.1136/gut.47.4.506 · Cited by 492
Clinical, biological, and histologic parameters as predictors of relapse in ulcerative colitis
Bitton, A., Peppercorn, M. A., Antonioli, D. A., Niles, J. L., Shah, S., Bousvaros, A., Ransil, B., Wild, G., Cohen, A., Deb Edwardes, M. D., et al. (2001) · Gastroenterology · doi:10.1053/gast.2001.20912 · Cited by 490
Role of fecal calprotectin as a biomarker of intestinal inflammation in inflammatory bowel disease
Konikoff, M. R., & Denson, L. A. (2006) · Inflammatory Bowel Diseases · doi:10.1097/00054725-200606000-00013 · Cited by 453
Tibble, J. A., Sigthorsson, G., Foster, R., Forgacs, I., & Bjarnason, I. (2002) · Gastroenterology · doi:10.1053/gast.2002.34755 · Cited by 441
A. G. Røseth, P. N. S. (1999) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365529950172835 · Cited by 422
Diagnostic Precision of Fecal Calprotectin for Inflammatory Bowel Disease and Colorectal Malignancy
von Roon, A. C., Karamountzos, L., Purkayastha, S., Reese, G. E., Darzi, A. W., Teare, J. P., Paraskeva, P., & Tekkis, P. P. (2007) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2007.01126.x · Cited by 401
Role of faecal calprotectin as non-invasive marker of intestinal inflammation
Costa, F., Mumolo, M. G., Bellini, M., Romano, M. R., Ceccarelli, L., Arpe, P., Sterpi, C., Marchi, S., & Maltinti, G. (2003) · Digestive and Liver Disease · doi:10.1016/s1590-8658(03)00381-5 · Cited by 289
Røseth, A. G., Aadland, E., & Grzyb, K. (2004) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365520410007971 · Cited by 267
Gisbert, J. P., & McNicholl, A. G. (2009) · Digestive and Liver Disease · doi:10.1016/j.dld.2008.05.008 · Cited by 238
Self-citationBunn, S. K., Bisset, W. M., Main, M. J. C., Gray, E. S., Olson, S., & Golden, B. E. (2001) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1002/j.1536-4801.2001.tb07395.x · Cited by 237
Calprotectin and lactoferrin in the assessment of intestinal inflammation and organic disease
D’Incà, R., Dal Pont, E., Di Leo, V., Ferronato, A., Fries, W., Vettorato, M. G., Martines, D., & Sturniolo, G. C. (2007) · International Journal of Colorectal Disease · doi:10.1007/s00384-006-0159-9 · Cited by 215
Established and emerging biological activity markers of inflammatory bowel disease
Nielsen, O. (2000) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(99)00849-7 · Cited by 195
Limburg, P. (2000) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(00)01987-0 · Cited by 171
Non-invasive investigation of inflammatory bowel disease
Tibble, J. (2001) · World Journal of Gastroenterology · doi:10.3748/wjg.v7.i4.460 · Cited by 167
Fecal Calprotectin Levels in Healthy Children Studied With an Improved Assay
Fagerberg, U. L., Lööf, L., Merzoug, R. D., Hansson, L., & Finkel, Y. (2003) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1002/j.1536-4801.2003.tb12040.x · Cited by 163
The role of C-reactive protein as an inflammatory marker in gastrointestinal diseases
Vermeire, S., Van Assche, G., & Rutgeerts, P. (2005) · Nature Clinical Practice Gastroenterology & Hepatology · doi:10.1038/ncpgasthep0359 · Cited by 149
Langhorst, J., Elsenbruch, S., Mueller, T., Rueffer, A., Spahn, G., Michalsen, A., & Dobos, G. J. (2005) · Inflammatory Bowel Diseases · doi:10.1097/01.mib.0000187980.08686.18 · Cited by 147
Review article: biological activity markers in inflammatory bowel disease
Desai, D., Faubion, W. A., & Sandborn, W. J. (2007) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2006.03184.x · Cited by 146
Walker, T. R., Land, M. L., Kartashov, A. I., Saslowsky, T. M., Lyerly, D. M., Boone, J. H., & Rufo, P. A. (2007) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/mpg.0b013e3180308d8e · Cited by 141
Fecal calprotectin is useful in predicting disease relapse in pediatric inflammatory bowel disease
Walkiewicz, D., Werlin, S. L., Fish, D. L., Scanlon, M. C., Hanaway, P. J., & Kugathasan, S. (2008) · Inflammatory Bowel Diseases · doi:10.1002/ibd.20376 · Cited by 135
Canani, R. B., de Horatio, L. T., Terrin, G., Romano, M. T., Miele, E., Staiano, A., Rapacciuolo, L., Polito, G., Bisesti, V., Manguso, F., et al. (2005) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/01.mpg.0000187818.76954.9a · Cited by 129
Faecal markers in the assessment of activity in inflammatory bowel disease
Poullis, A. P., Foster, F., Northfield, T. C., & Mendall, M. A. (2002) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.2002.01196.x · Cited by 128
Enzymes in feces: Useful markers of chronic inflammatory bowel disease
Angriman, I., Scarpa, M., Renata D'Incà, Basso, D., Ruffolo, C., Polese, L., Sturniolo, G. C., D'Amico, D. F., & Plebani, M. (2007) · Clinica Chimica Acta · doi:10.1016/j.cca.2007.02.025 · Cited by 119
Fecal leukocyte proteins in inflammatory bowel disease and irritable bowel syndrome.
Silberer, H., Küppers, B., Mickisch, O., Baniewicz, W., Drescher, M., Traber, L., Kempf, A., & Schmidt‐Gayk, H. (2005) · PubMed · Cited by 114
Fecal Lactoferrin and Calprotectin After Ileocolonic Resection for Crohn's Disease
Scarpa, M., Renata D'Incà, Basso, D., Ruffolo, C., Polese, L., Bertin, E., Luise, A., Frego, M., Plebani, M., Sturniolo, G. C., et al. (2007) · Diseases of the Colon & Rectum · doi:10.1007/s10350-007-0225-6 · Cited by 97
Lundberg, J. O., Hellström, P. M., Fagerhol, M. K., Weitzberg, E., & Røseth, A. G. (2005) · Nature Clinical Practice Gastroenterology & Hepatology · doi:10.1038/ncpgasthep0094 · Cited by 82
Clinical Remission in Crohn’s Disease – Assessment Using Faecal 111 ln Granulocyte Excretion
Saverymuttu, S. H. (2009) · Digestion · doi:10.1159/000199277 · Cited by 59
Papel de los marcadores biológicos en la enfermedad inflamatoria intestinal
Gisbert, J. P., González‐Lama, Y., & Maté, J. (2007) · Gastroenterología y Hepatología · doi:10.1157/13100073 · Cited by 45
Self-citationFaecal Parameters in the Assessment of Activity in Inflammatory Bowel Disease
Veer, A. V. D. S. (1999) · Scandinavian Journal of Gastroenterology · doi:10.1080/003655299750025624 · Cited by 42
Gisbert, J. P., Gomollón, F., Maté, J., & Pajares, J. M. (2003) · Gastroenterología y Hepatología · doi:10.1016/s0210-5705(03)70365-3 · Cited by 20
Self-citation
Cited by
Magro, F., Gionchetti, P., Eliakim, R., Ardizzone, S., Armuzzi, A., Barreiro-de Acosta, M., Burisch, J., Gecse, K. B., Hart, A. L., Hindryckx, P., et al. (2017) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjx008 · Cited by 1,910
Peyrin-Biroulet, L., Sandborn, W., Sands, B. E., Reinisch, W., Bemelman, W., Bryant, R. V., D'Haens, G., Dotan, I., Dubinsky, M., Feagan, B., et al. (2015) · American Journal of Gastroenterology · doi:10.1038/ajg.2015.233 · Cited by 1,844
Maaser, C., Sturm, A., Vavricka, S. R., Kucharzik, T., Fiorino, G., Annese, V., Calabrese, E., Baumgart, D. C., Bettenworth, D., Borralho Nunes, P., et al. (2019) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjy113 · Cited by 1,823
Self-citationDignass, A., Eliakim, R., Magro, F., Maaser, C., Chowers, Y., Geboes, K., Mantzaris, G., Reinisch, W., Colombel, J.-F., Vermeire, S., et al. (2012) · Journal of Crohn's and Colitis · doi:10.1016/j.crohns.2012.09.003 · Cited by 888
A review of the diagnosis, prevention, and treatment methods of inflammatory bowel disease
Saeid Seyedian, S., Alimentary Tract Research Center, A. J. U. O. M. S., Nokhostin, F., Faculty of Medicine, A. J. U. O. M. S., Forogh Nokhostin, A. P. O. I. M., Dargahi Malamir, M., & Faculty of Medicine, M. D. O. I. M. (2019) · Journal of Medicine and Life · doi:10.25122/jml-2018-0075 · Cited by 817
Metadata
- Authors
- Gisbert, J. P., Bermejo, F., Pérez-Calle, J.-L., Taxonera, C., Vera, I., McNicholl, A. G., Algaba, A., López, P., López-Palacios, N., Calvo, M., González-Lama, Y., Carneros, J.-A., Velasco, M., & Maté, J.
- Venue
- Inflammatory Bowel Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2009-08
- Volume
- 15
- Issue
- 8
- Pages
- 1190-1198
- ISSN
- 1078-0998 (ISSN-L)
- OpenAlex
- W2077570588
- Cited by
- 315
- References
- 40
- FWCI
- 10.16
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.